knowledge -WSS

knowledge

author：comprehensive 2025-10-03 00:04:27 - browse：196

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

leisure time

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

Walmart eyes Medicare Advantage provider ChenMed

Generate Biomedicines machine learning biotech raises $273M

Using force crossed my mind when examining a defiant young patient

CDC panel: People 65 and older should get a Covid spring booster shot

How medical schools plan to diversify without affirmative action

focus

knowledge

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Children’s Hospital revives plan for pedestrian bridge

Peter Hotez and the public health issue of online harassment

Elisabeth Bik tackles the widespread issue of research misconduct

Psychedelics group wrestles with new pharma identity

Popular nasal decongestant doesn't actually relieve congestion

Medicare proposal to cover medical devices draws a mixed reaction

STAT Madness 2024: Meet the contenders

Sports medicine is finally prioritizing gender equality

Children’s Hospital revives plan for pedestrian bridge

hotspot

Telehealth for opioid use disorder is lifesaving

CDC advisory group OKs chikungunya vaccine

FDA panel endorses Alnylam’s heart drug — after picking it apart

Regeneron agrees to White House price limits on anti

Regeneron agrees to White House price limits on anti

Childhood vaccination ad campaign launches in the U.K.

leisure time

leisure time

focus

entertainment